Scarpignato C, Gatta L, Zullo A, Blandizzi C, SIF-AIGO-FIMMG Group. Effective and safe proton pump inhibitor therapy in acid-related diseases—a position paper addressing benefits and potential harms of acid suppression. BMC Med. 2016;14(1):179. https://doi.org/10.1186/s12916-016-0718-z.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ardoino I, Casula M, Molari G, Mucherino S, Orlando V, Menditto E, Franchi C. Prescription appropriateness of drugs for peptic ulcer and gastro-esophageal reflux disease: baseline assessment in the LAPTOP-PPI cluster randomized trial. Front Pharmacol. 2022;13: 803809. https://doi.org/10.3389/fphar.2022.803809.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wallerstedt SM, Fastbom J, Linke J, Vitols S. Long-term use of proton pump inhibitors and prevalence of disease- and drug-related reasons for gastroprotection—a cross-sectional population-based study. Pharmacoepidemiol Drug Saf. 2017;26(1):9–16. https://doi.org/10.1002/pds.4135.

Article  CAS  PubMed  Google Scholar 

Jaynes M, Kumar AB. The risks of long-term use of proton pump inhibitors: a critical review. Ther Adv Drug Saf. 2018;10:2042098618809927. https://doi.org/10.1177/2042098618809927.

Article  PubMed  PubMed Central  Google Scholar 

Nguyen PV, Tamaz R. Inappropriate prescription of proton pump inhibitors in a community setting. Can J Hosp Pharm. 2018;71(4):267–71. https://doi.org/10.4212/cjhp.v71i4.2828.

Article  PubMed  PubMed Central  Google Scholar 

Voukelatou P, Vrettos I, Emmanouilidou G, Dodos K, Skotsimara G, Kontogeorgou D, et al. Predictors of inappropriate proton pump inhibitors use in elderly patients. Curr Gerontol Geriatr Res. 2019;2019:7591045. https://doi.org/10.1155/2019/7591045.

Article  PubMed  PubMed Central  Google Scholar 

Franchi C, Mannucci PM, Nobili A, Ardoino I. Use and prescription appropriateness of drugs for peptic ulcer and gastrooesophageal reflux disease in hospitalized older people. Eur J Clin Pharmacol. 2020;76(3):459–65. https://doi.org/10.1007/s00228-019-02815-w.

Article  CAS  PubMed  Google Scholar 

Shiraev TP, Bullen A. Proton pump inhibitors and cardiovascular events: a systematic review. Heart Lung Circ. 2018;27:443–50. https://doi.org/10.1016/j.hlc.2017.10.020.

Article  PubMed  Google Scholar 

Shah NH, LePendu P, Bauer-Mehren A, Ghebremariam YT, Iyer SV, Marcus J, et al. Proton pump inhibitor usage and the risk of myocardial infarction in the general population. PLoS ONE. 2015;10(6): e0124653. https://doi.org/10.1371/journal.pone.0124653.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wang YF, Chen YT, Luo JC, Chen TJ, Wu JC, Wang SJ. Proton-pump inhibitor use and the risk of first-time ischemic stroke in the general population: a nationwide population-based study. Am J Gastroenterol. 2017;112(7):1084–93. https://doi.org/10.1038/ajg.2017.101.

Article  CAS  PubMed  Google Scholar 

Casula M, Scotti L, Galimberti F, et al. Use of proton pump inhibitors and risk of ischemic events in the general population. Atherosclerosis. 2018;277:123–9. https://doi.org/10.1016/j.atherosclerosis.2018.08.035.

Article  CAS  PubMed  Google Scholar 

Xie Y, Bowe B, Yan Y, et al. Estimates of all cause mortality and cause specific mortality associated with proton pump inhibitors among US veterans: cohort study. BMJ. 2019;365: l1580. https://doi.org/10.1136/bmj.l1580.

Article  PubMed  PubMed Central  Google Scholar 

Ho PM, Maddox TM, Wang L, Fihn SD, Jesse RL, Peterson ED, et al. Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome. JAMA. 2009;301(9):937–44. https://doi.org/10.1001/jama.2009.261.

Article  CAS  PubMed  Google Scholar 

van Boxel OS, van Oijen MGH, Hagenaars MP, Smout AJPM, Siersema PD. Cardiovascular and gastrointestinal outcomes in clopidogrel users on proton pump inhibitors: results of a large Dutch cohort study. Am J Gastroenterol. 2010;105(11):2430–6. https://doi.org/10.1038/ajg.2010.334.

Article  CAS  PubMed  Google Scholar 

Westergaard N, Tarnow L, Vermehren C. Use of clopidogrel and proton pump inhibitors alone or in combinations in persons with diabetes in Denmark; potential for CYP2C19 genotype-guided drug therapy. Metabolites. 2021;11(2):96. https://doi.org/10.3390/metabo11020096.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Charlot M, Ahlehoff O, Norgaard ML, et al. Proton-pump inhibitors are associated with increased cardiovascular risk independent of clopidogrel use: a nationwide cohort study. Ann Intern Med. 2010;153(6):378–86. https://doi.org/10.7326/0003-4819-153-6-201009210-00005.

Article  PubMed  Google Scholar 

Charlot M, Grove EL, Hansen PR, Olesen JB, Ahlehoff O, Selmer C, et al. Proton pump inhibitor use and risk of adverse cardiovascular events in aspirin treated patients with first time myocardial infarction: nationwide propensity score matched study. BMJ. 2011;342: d2690. https://doi.org/10.1136/bmj.d2690.

Article  PubMed  PubMed Central  Google Scholar 

Batchelor R, Kumar R, Gilmartin-Thomas JFM, et al. Systematic review with meta-analysis: risk of adverse cardiovascular events with proton pump inhibitors independent of clopidogrel. Aliment Pharmacol Ther. 2018;48:780–96. https://doi.org/10.1111/apt.14955.

Article  CAS  PubMed  Google Scholar 

Farhat N, Fortin Y, Haddad N, et al. Systematic review and meta-analysis of adverse cardiovascular events associated with proton pump inhibitors used alone or in combination with antiplatelet agents. Crit Rev Toxicol. 2019;49:215–61. https://doi.org/10.1080/10408444.2019.1583167.

Article  PubMed  Google Scholar 

Li S, Liu F, Chen C, et al. Real-world relationship between proton pump inhibitors and cerebro-cardiovascular outcomes independent of clopidogrel. Int Heart J. 2019;60:910–8. https://doi.org/10.1536/ihj.18-584.

Article  CAS  PubMed  Google Scholar 

Davis TME, Drinkwater J, Davis WA. Proton pump inhibitors, nephropathy, and cardiovascular disease in type 2 diabetes: the Fremantle diabetes study. J Clin Endocrinol Metab. 2017;102(8):2985–93. https://doi.org/10.1210/jc.2017-00354.

Article  PubMed  Google Scholar 

Trang A, Bushman J, Halalau A. Effect of long-term proton pump inhibitor use on glycemic control in patients with type two diabetes mellitus. J Diabetes Res. 2021;2021:5578265. https://doi.org/10.1155/2021/5578265.

Article  PubMed  PubMed Central  Google Scholar 

Geng T, Chen J-X, Zhou Y-F, Lu Q, Wan Z, Liu L, et al. Proton pump inhibitor use and risks of cardiovascular disease and mortality in patients with type 2 diabetes. J Clin Endocrinol Metab. 2023;108(6):e216–22. https://doi.org/10.1210/clinem/dgac750.

Article  PubMed  Google Scholar 

Robusto F, Lepore V, D’Ettorre A, Lucisano G, De Berardis G, Bisceglia L, et al. The Drug Derived Complexity Index (DDCI) predicts mortality, unplanned hospitalization and hospital readmissions at the population level. PLoS ONE. 2016;11(2): e0149203. https://doi.org/10.1371/journal.pone.0149203.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Harding JL, Pavkov ME, Magliano DJ, Shaw JE, Gregg EW. Global trends in diabetes complications: a review of current evidence. Diabetologia. 2019;62(1):3–16. https://doi.org/10.1007/s00125-018-4711-2.

Article  PubMed  Google Scholar 

Sehested TSG, Gerds TA, Fosbøl EL, et al. Long-term use of proton pump inhibitors, dose-response relationship and associated risk of ischemic stroke and myocardial infarction. J Intern Med. 2018;283(3):268–81. https://doi.org/10.1111/joim.12698.

Article  CAS  PubMed  Google Scholar 

Tseng H-J, Cheng C-M, Tsai S-J, Lin W-C, Bai Y-M, Tsai C-F, et al. Proton pump inhibitor exposure and acute myocardial infarction risk: a nested cohort study. Cardiovasc Toxicol. 2021;21:444–50. https://doi.org/10.1007/s12012-021-09637-2.

Article  CAS  PubMed  Google Scholar 

Holmes DR, Dehmer GJ, Kaul S, Leifer D, O’Gara PT, Stein CM. ACCF/AHA clopidogrel clinical alert: approaches to the FDA “boxed warning”: a report of the American College of Cardiology Foundation Task Force on clinical expert consensus documents and the American Heart Association endorsed by the Society for Cardiovascular Angiography and Interventions and the Society of Thoracic Surgeons. J Am Coll Cardiol. 2010;56(4):321–41. https://doi.org/10.1016/j.jacc.2010.05.013.

Article  CAS  PubMed  Google Scholar 

Ghebremariam YT, LePendu P, Lee JC, Erlanson DA, Slaviero A, Shah NH, et al. Unexpected effect of proton pump inhibitors: elevation of the cardiovascular risk factor asymmetric dimethylarginine. Circulation. 2013;128(8):845–53. https://doi.org/10.1161/CIRCULATIONAHA.113.003602.

Article  CAS  PubMed  Google Scholar 

Cooke JP, Ghebremariam YT. DDAH says NO to ADMA. Arterioscler Thromb Vasc Biol. 2011;31(7):1462–4. https://doi.org/10.1161/ATVBAHA.111.228833.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cooke JP. DDAH: a target for vascular therapy? Vasc Med. 2010;15(3):235–8. https://doi.org/10.1177/1358863X10362605.

Article  PubMed  PubMed Central  Google Scholar 

Yepuri G, Sukhovershin R, Nazari-Shafti TZ, Petrascheck M, Ghebre YT, Cooke JP. Proton pump inhibitors accelerate endothelial senescence. Circ Res. 2016;118:e36-42.

Article  CAS  PubMed